[Effects of lovastatin in primary hypercholesterolemia].
Lovastatin, a potent inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme-A-reductase, was investigated in a placebo-controlled trial of 26 primary hypercholesterolemic subjects. Drug dosage varied from 20 to 40 mg/d in a single dose on a 12 weeks treatment period. Average plasma cholesterol reduction levels were 17 and 31%, and LDL-cholesterol 24 and 41% on 20 and 40 mg/d respectively. High-density lipoprotein and triglycerides levels did not change significantly. Similar mean decreases in total plasma cholesterol and LDL-cholesterol levels were observed in hypercholesterolemics irrespectively of being of familial origin or not. No serious clinical and laboratory abnormalities were observed. In this study, lovastatin was a well tolerated and effective agent for the treatment of non familial and heterozygous familial hypercholesterolemia.
Nakandakare
E R
ER
Garcia
R C
RC
Carré
J M
JM
Zerbinatti
C V
CV
Oliveira
H C
HC
Quintão
E C
EC
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000096:biosynthesis / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008148:Lovastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D008078:Cholesterol, LDL; D002784:Cholesterol; D008148:Lovastatin
Efeitos da lovastatina na hipercolesterolemia primária.